Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
agomiR-206
- Development stage
- Preclinical
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intralesional, Intranasal, Intravenous
01
Overview
agomiR-206 is a chemically modified, synthetic double-stranded RNA mimetic of microRNA-206 (miR-206). It is designed to mimic endogenous mature miR-206, facilitating gain-of-function studies in vitro and in vivo. miR-206 is a key post-transcriptional regulator implicated in myogenesis, osteogenesis, and various pathological conditions. By binding to the 3' untranslated regions (3' UTRs) of target mRNAs, agomiR-206 suppresses the translation or induces the degradation of several key proteins, including gap junction alpha-1 protein (Connexin 43), brain-derived neurotrophic factor (BDNF), DNA methyltransferase 3 alpha (DNMT3A), bone morphogenetic protein 3 (BMP3), and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1). In preclinical research, agomiR-206 has been investigated for its therapeutic potential in attenuating fibrous dysplasia, promoting bone regeneration in orofacial bone deformities, and regulating infantile hemangioma, depression, and Alzheimer's disease.
- Other names
- agomiR miR-206agomiR-206-3pagomiR206-3pagomiR 206-3pmicroRNA-206 agomirmicroRNA206 agomirmicroRNA 206 agomir
02
Targets
BMP (Bone morphogenetic protein family)BDNF (Brain-derived neurotrophic factor)DDX5 (Phosphorylated-p68 RNA helicase)DNMT3A (DNA methyltransferase 3 alpha)GJA1 (Connexin43 Hemichannel)NFATC1SFRP1 (Secreted frizzled-related protein 1)
Beyond the preview
Go deeper on agomiR-206.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on agomiR-206.